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Abstract
Objectives—It is not known whether current use of the medication primidone affects brain 
gamma-aminobutyric acid (GABA) concentrations. This is an important potential confound in 
studies of the pathophysiology of essential tremor (ET), one of the most common neurological 
diseases. We compared GABA concentrations in the dentate nucleus in 6 ET patients taking 
primidone vs. 26 ET patients not taking primidone.
Methods—1H magnetic resonance spectroscopy (MRS) was performed using a 3.0 Tesla 
Siemens Tim Trio scanner. The MEGA-PRESS J-editing sequence was used for GABA detection 
in two cerebellar volumes of interest (left and right) that included the dentate nucleus.
Results—The right dentate GABA concentration was similar in the two groups (2.21 ± 0.46 [on 
primidone] vs. 1.93 ± 0.39 [not on primidone], p=0.15), as was the left dentate GABA 
concentration (1.61 ± 0.35 [on primidone] vs. 1.67 ± 0.34 [not on primidone], p=0.72). The daily 
primidone dose was not associated with either right or left dentate GABA concentrations 
(respective p = 0.89 and 0.76).
Conclusions—We did not find a difference in dentate GABA concentrations between 6 ET 
cases taking daily primidone and 26 ET cases not taking primidone. Furthermore, there was no 
association between daily primidone dose and dentate GABA concentration. These data suggest 
that it is not necessary to exclude ET patients on primidone from MRS studies of dentate GABA 
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concentration and, if assessment of these concentrations were to be developed as a biomarker for 
ET, primidone usage would not confound interpretation of the results.
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Introduction
Despite its high prevalence, essential tremor (ET) is among the most poorly understood 
neurological diseases. On the most basic biological level, little is known about its underlying 
pathologic-anatomy and pathophysiology.1 Several recent postmortem studies report a 30 - 
40% reduction in Purkinje cells (PCs) in ET, suggesting that on a mechanistic level, this 
common neurological disease could be neurodegenerative.2–6 However, the presence and 
extent of PC loss in ET is the subject of considerable controversy,7 and therefore, the focus 
of current scrutiny.
PCs are a major storehouse of brain gamma-aminobutyric acid (GABA), releasing GABA 
into the synaptic cleft at the level of the cerebellar dentate nucleus.8, 9 Thus, the cerebellar 
dentate GABA level could be a convenient in vivo marker of PC number. At present, we are 
conducting a longitudinal study that uses in-vivo magnetic resonance spectroscopy (MRS) to 
quantify GABA concentrations in the cerebellar dentate nucleus. We expect that the 
proposed research, by testing the hypothesis that these concentrations will be low in ET 
patients compared to age-matched controls, will elucidate a critically important question 
about the underlying pathophysiology of ET. Aside from its scientific value, demonstrating 
low MRS-assessed GABA concentrations in ET could have an important clinical implication 
- MRS-assessed GABA concentration could serve as an imaging biomarker for ET. No such 
biomarkers currently exist.
Yet there is a complication. A potential contraindication for enrollment in this and other 
such studies is current exposure to medications that could influence brain GABA-ergic 
neurotransmission. By far, the most commonly used of these agents in ET is primidone, 
which is one of only two front-line medications used to treat ET.10, 11 Studies estimate that 
approximately 50% of all ET patients have tried primidone.12 Primidone is metabolized to 
phenobarbital, which binds to the GABAA receptor, potentiating GABA-ergic 
neurotransmission.13 The question, which we now address, is whether current use of 
primidone affects dentate GABA concentrations. To our knowledge, this is unknown. The 
issue is an important one – if one were to exclude such treated ET patients, the potential loss 
of patients would be as much as 50%. In this cross-sectional study, we compared GABA 
concentrations in two cerebellar volumes of interest (left and right), which included the 
dentate nucleus, comparing 6 ET patients taking daily primidone to 26 ET patients who were 
not taking primidone.
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Materials and Methods
Subjects and clinical evaluation
ET cases were recruited from several sources, including a clinical-epidemiological study of 
ET,14 one of the author’s (E.D.L.) neurological practices, and study advertisements. 
Inclusion criteria were: (1) a prior diagnosis of ET assigned by a treating neurologist, (2) 
willingness to undergo a magnetic resonance imaging (MRI) scan as part of the current 
baseline study as well as in a longitudinal study, and (3) living within two hours of the 
recruiting site. Exclusion criteria were: (1) heavy exposure to ethanol (as defined 
previously),15 (2) history of a neurodegenerative disease (Parkinson’s disease, Alzheimer’s 
disease), (3) prior deep brain stimulation or other neurosurgery (e.g., gamma knife, 
thalamotomy) for ET, (4) a reason to be excluded from MRI scanning (e.g., metal in their 
bodies). Furthermore, we excluded most cases who were taking medications that bind to the 
GABAA receptor or that enhance GABA tone (e.g., clonazepam, diazepam, gabapentin, 
phenobarbital, primidone, progabide, propofol, tigabine, valproate, vigabatrin); however, a 
small number of cases who were taking primidone were enrolled specifically for the 
purposes of the present analyses. In total, 106 ET cases were excluded for one of the 
aforementioned reasons.
Once enrolled, a trained research assistant conducted an in-person evaluation, administering 
demographic (e.g., age, gender, race, education) and medical history questionnaires (e.g., 
hand-dominance, smoking history, tremor duration, number of drinks of ethanol per month). 
The Montreal Cognitive Assessment (MoCA) was performed as a brief assessment of 
cognitive function.16 During the in-person assessment, a videotaped neurological 
examination was also performed. This included one test for postural tremor and five for 
kinetic tremor (12 tests total). A senior neurologist specializing in movement disorders 
(E.D.L.) used a reliable and valid clinical rating scale, the Washington Heights-Inwood 
Genetic Study of ET (WHIGET) tremor rating scale, to rate postural and kinetic tremor 
during each test: 0 (none), 1 (mild), 2 (moderate), 3 (severe), resulting in a total tremor score 
(range = 0 – 36).17 Diagnoses of ET were re-confirmed by E.D.L. using the videotaped 
neurological examination and WHIGET diagnostic criteria (moderate or greater amplitude 
kinetic tremor [tremor rating ≥ 2] during three or more tests or a head tremor, in the absence 
of Parkinson’s disease, dystonia or another cause).18, 19
The study protocol was reviewed and approved by the Human Subjects Institutional Review 
Board at Yale University, Purdue University and at Weill Cornell Medical College. Written 
informed consent was obtained from each subject prior to participation in the study.
In vivo MRI/MRS measurements
MRI and 1H MRS exams were performed on a 3.0 Tesla Siemens Tim Trio scanner 
(Siemens Healthcare, Erlangen, Germany), equipped with a 32-channel head coil. All scans 
were performed at Weill Cornell Medical College. Fast T2-weighted images were acquired 
in all three orientations to ensure exact localization of the MRS volumes of interest (VOIs). 
GABA-edited MRS data was acquired from two VOIs containing the left and right 
cerebellar dentate nucleus, respectively (both 25 mm × 25 mm × 25 mm, 128 averages) 
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(Figure 1). Both dentate nuclei were clearly identified on the T2-weighted images on both 
axial and coronal planes. Each GABA VOI was placed on the axial plane such that the entire 
dentate nucleus was included, given the fact that this is the level at which the Purkinje cells 
release their GABA into the synaptic cleft,8 while minimizing contributions from vascular 
and CSF compartments. The VOI was then confirmed to be completely within the 
cerebellum on the coronal plane. The MEGA-PRESS J-editing sequence was used for 
GABA detection (TR/TE = 1500/68 ms).20
196 averages were acquired with the spectrally selective editing pulse centered at 1.9 ppm 
(edit-on) and 196 averages with the pulse centered at 7.5 ppm (edit-off) in an interleaved 
fashion. The resulting difference spectrum contains a GABA peak at 3.0 ppm, which also 
includes contributions from co-edited macromolecules and homocarnosine, a dipeptide 
consisting of GABA and histidine. Therefore, the signal will be referred to as GABA+. For 
both VOIs, a reference spectrum was acquired without water suppression. These reference 
spectra were then used for phase and frequency correction of the corresponding water-
suppressed spectra. FASTESTMAP shimming (IPR#577; Siemens Healthcare) was 
performed before each voxel measurement to achieve water line widths of < 20 Hz.21 In 
order to determine voxel tissue composition, high-resolution MPRAGE images were 
acquired (TR/TE/TI = 2300/2.91/900 ms, flip angle = 9°, bandwidth: 240 Hz/pixel, voxel 
size: 1.0 mm × 1.0 mm × 1.2 mm, GRAPPA = 2). Every effort was made to ensure the 
subjects were as comfortable as possible in the scanner.
Data processing and analysis
MRS data processing and quantification were performed with LCModel 6.3-0L,22 fitting 
each spectrum as a weighted linear combination of basis spectra from individual 
metabolites. For fitting the MEGA-PRESS spectra, basis sets were generated from density 
matrix simulations of the sequence using published values for chemical shifts and J-
couplings from Kaiser et al.,23 with an exact treatment of metabolite evolution during the 
two frequency-selective MEGA inversion pulses. LCModel fitting %SD values were lower 
than 20% for GABA+ in all spectra. GABA+ concentrations were derived from raw GABA
+ output values from LCModel, multiplied with a water calibration factor provided by 
LCModel (FCALIB factor). Due to scaling uncertainties, GABA+ concentration values are 
given in institutional units, but are proportional to and in the range of the true GABA+ 
concentrations in mM.
To determine and correct for the tissue composition of the MRS voxels, MPRAGE images 
were segmented into grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF) 
using an in-house MATLAB 2013a (MathWorks Inc., Natick, MA, USA) code, incorporated 
with statistical parametric mapping (SPM8, Wellcome Department of Imaging 
Neuroscience, London, UK). GABA levels corrected for CSF were obtained using the 
method described by Chowdhury et al.24
Sample size calculation
In order to calculate sample size, we used our won pilot MRS data on dentate GABA 
concentration in five ET cases who were not taking primidone. We determined that with 6 
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treated and 26 untreated cases, we would have 80% power to detect as little as a 25% 
difference in dentate GABA concentration between groups (assuming a two-sided Student’s 
t test and alpha = 0.5). Given published data showing 50 – 70% increases in MRS-assessed 
brain GABA concentrations in animals and humans treated with GABA-ergic 
medications,25–28 this sample size was considered adequate.
Statistical analyses
All analyses were performed in SPSS (version 21.0). We used Student’s t tests, Fisher’s 
exact tests, and Mann Whitney tests (for variables that were not normally distributed) to 
compare the demographic and clinical features of ET cases on primidone vs. ET cases off 
primidone (Table 1). We also assessed the correlations between dentate GABA 
concentration and demographic and clinical features using Student’s t tests as well as 
correlation coefficients (Pearson’s for normally distributed variables and Spearman’s for 
variables that were not normally distributed) (Table 2). In linear regression models, we 
adjusted for potential confounds (i.e., variables that were associated, even to a marginal 
degree, with primidone status or with dentate GABA concentration) in the association 
between primidone status (treated vs. untreated) and dentate GABA concentrations 
(dependent variable).
Results
The two groups were similar to one another in terms of age, gender, race, education, 
smoking status, hand dominance, total tremor score, and MoCA score (Table 1). The mean 
tremor duration was nearly 10 years longer for the primidone group, although this difference 
did not reach statistical significance (Table 1). The median number of drinks of ethanol was 
greater for the primidone group (21.5 vs. 3.2), but this difference did not reach statistical 
significance either (Table 1).
In our 32 cases, dentate GABA concentration was not correlated with age, gender, years of 
education, total tremor score or median number of drinks of ethanol per month (Table 2). 
Higher right, but not left, dentate GABA concentration was weakly associated with lower 
MoCA score (r = -0.42, p = 0.03, Table 2). Higher left, but not right, dentate GABA 
concentration was marginally associated with longer tremor duration (r = 0.39, p = 0.06, 
Table 2).
Both, the right and left dentate GABA concentrations were similar in the two groups (right: 
2.21 ± 0.46 [on primidone] vs. 1.93 ± 0.39 [not on primidone], t = 1.49, p = 0.15; left: 1.61 
± 0.35 [on primidone] vs. 1.67 ± 0.34 [not on primidone], t = 0.36, p = 0.72) (Figure 2).
In the six treated cases, the daily primidone dose ranged from 50 to 750 mg (mean = 312.5 
mg, standard deviation = 309.2 mg); there was no association between this dose and either 
right dentate GABA concentration (Pearson’s r = 0.11, p = 0.89) or left dentate GABA 
concentration (Pearson’s r = -0.24, p = 0.76).
In a linear regression model that adjusted for potential confounds (number of drinks of 
ethanol per month, tremor duration, MoCA score), taking primidone was not associated with 
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the right dentate GABA concentration (beta = 0.27, p = 0.17). Similarly, adjusting for the 
same potential confounds, taking primidone was not associated with the left dentate GABA 
concentration (beta = -0.24, p = 0.22).
Discussion
To our knowledge, this is the first study to examine the effects of current, daily 
administration of primidone on MRS-assessed dentate GABA concentration. The current 
data address a question about a major potential confound in studies of GABA in ET. 
Importantly, we did not find a difference in dentate GABA concentrations in 6 ET cases 
taking daily primidone compared to 26 ET cases who were not taking primidone. 
Furthermore, there was no association between daily primidone dose and dentate GABA 
concentration.
The published literature has not directly addressed the issue we focus on in this study. 
Indeed, the small number of related published studies differ from ours in numerous respects 
and their results are mixed. These data will be reviewed in the paragraphs below, beginning 
with the human studies and then moving to the animal studies.
In an MRS study, 17 healthy adults were randomly assigned to receive one of the following 
medications with GABA-ergic properties: topiramate, gabapentin or lamotrigine. GABA 
was measured using a 4.1-T magnet from a 13.5-mL volume over the occipital region 3 and 
6 hours following administration of an acute single dose and 2 and 4 weeks after dose 
titration. During the acute phase, GABA concentrations rose 70% (topiramate) and 48% 
(gabapentin), but not with lamotrigine. With long term dosing, significant elevations in 
GABA were observed compared to baseline for all three drugs (topiramate 46%, gabapentin 
25%, and lamotrigine 25%).25 The study differed from ours in the sense that the patients 
were not ET patients, the medication of interest in our study (primidone) was not studied, 
and GABA concentrations in a VOI containing the dentate nucleus were not assessed.
In another study, the authors performed a 900 mg gabapentin single-dose challenge in 
healthy human subjects in order to explore its effects on GABA concentrations measured 
with ¹H-MRS in the visual cortex. Gabapentin administration was associated with an 
average increase in GABA concentration of 55.7% (range = 6.9 -91.0%).26 That study 
differed from ours in multiple respects, including the specific medication used, the study 
population (ET vs. controls), the chronicity of drug usage (single-dose vs. chronic use) and 
the location of the MRS voxel.
In another study, the effects of gabapentin and vigabatrin were assessed on GABA 
concentrations in human (n = 14) and rat (n = 6) neocortical slice preparations. Neocortical 
slices were incubated with gabapentin, vigabatrin or no drugs for 3 hours. Proton MRS of 
perchloric acid (PCA) extracts was used to measure GABA concentrations. Vigabatrin 
increased cellular GABA concentrations in both human and rat neocortical slices by 62% (p 
<0.001) and 88% (p <0.03), respectively. Gabapentin significantly increased GABA 
concentrations by 13% (p <0.02) in human neocortical slices but not in rat neocortical 
slices.27
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In another study, the effects of gabapentin, pregabalin and vigabatrin on brain MRS GABA 
concentrations were studied in Long Evans rats. Two hours after intraperitoneal injection of 
100mg/kg gabapentin no differences were observed in GABA concentrations in rats treated 
with gabapentin. For pregabalin, no effect was observed. Vigabatrin produced a 50% 
increase in GABA. The authors concluded that although gabapentin and pregabalin are 
anticonvulsants designed to mimic GABA, these drugs do not raise GABA levels acutely.29
In an earlier study 28 of albino mice, the authors administered primidone and measured brain 
GABA levels in the cerebral hemispheres. This is the only study we are aware of that has 
focused on this medication (primidone), as did we. They found that primidone (50 mg/kg 
intra-peritoneally) did not raise the brain GABA concentrations in these animals.
Overall, one can see that the results are mixed with respect to animal vs. human data, with 
respect to the effects of specific GABA-ergic agents relative to one another, and with respect 
to the acute vs. chronic effects of the same agents. The one study28 that assessed primidone; 
however, found that intra-peritoneally-delivered primidone did not raise the brain GABA 
concentrations.
This study had a number of limitations. First, our VOI was large compared to the size of the 
dentate nucleus. This was necessary in order to obtain a GABA-edited spectrum with 
sufficient signal to noise ratio for adequate quantification. Thus, it is conceivable that our 
sensitivity to detect very small changes in dentate GABA may have been insufficient, 
especially if the GABA concentration of the surrounding cerebellar tissue, which was co-
measured, did not change. Second, we did not precisely standardize when the six treated 
study subjects took their usual morning primidone dose. However, all six of them took their 
dose on the morning of the scan, and the latency between dose and scan ranged from 1 – 6 
hours. As noted above, in a study 28 of albino mice, the authors noted that primidone 
administered intra-peritoneally did not acutely raise brain GABA concentrations. Third, the 
number of study subjects taking primidone was small (n = 6). Despite this, we were powered 
to detect as little as a 25% difference between study groups. Given the available published 
data, which show 50 – 70% increases in MRS-assessed brain GABA concentrations in 
animals and humans treated with GABA-ergic medications,25–28 this sample size was 
considered more than adequate.
In summary, we did not find a difference in dentate GABA concentrations in 6 ET cases 
taking daily primidone compared to 26 ET cases who were not taking primidone. 
Furthermore, there was no association between daily primidone dose and dentate GABA 
concentration. These data suggest that it is not necessary to exclude ET patients on 
primidone from MRS studies of dentate GABA concentration and, if such concentrations 
were eventually to be developed as a biomarker for ET, that use of primidone would not 
confound the interpretation of the results.
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Figure 1. 
Top: Representative GABA-edited spectrum from the dentate VOI showing the raw data and 
the LCModel fit. Bottom: Placement of the GABA VOI, containing the left cerebellar 
dentate.
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Figure 2. 
GABA concentrations in the right dentate nuclei in ET patients on vs. off primidone (gray 
bars) and GABA concentrations in the left dentate nucleus in ET patients on vs. off 
primidone (black bars). Bars represent means and one standard deviation.
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Table 1
Demographic and clinical characteristics of ET cases who were taking primidone vs. ET cases who were not 
taking primidone
ET cases on
primidone (n = 6)
ET cases not on
primidone (n = 26)
Significance
Age (years) 78.7 ± 4.4 75.4 ± 6.6 p = 0.26 a
Female gender 2 (33.3) 11 (42.3) p = 1.00 b
White race 6 (100) 25 (96.2) p = 1.00 b
Education (years) 17.3 ± 4.8 17.7 ± 2.3 p = 0.79 a
Current smoker 0 (0.0) 0 (0.0) p = 1.00 b
Total tremor score 19.3 ± 5.5 21.8 ± 4.6 p = 0.27 a
Tremor duration (years) 42.3 ± 16.3 33.1 ± 21.9 p = 0.35 a
Right hand dominant 4 (75.0) 25 (96.2) p = 0.17 b
MoCA score 27.0 ± 2.6 27.1 ± 2.3 p = 0.97 a
Median number of drinks of ethanol per month 21.5 3.2 p = 0.097 c
Values represent numbers (percentages) or mean ± standard deviation.
aStudent’s t test.
b
Fisher’s exact test.
c
Mann-Whitney test.
MoCA = Montreal Cognitive Assessment
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Table 2
Correlation between dentate GABA concentration and demographic and clinical characteristics of ET cases
Right dentate GABA
concentration
Left dentate GABA
concentration
Age (years) rp = −0.006
p = 0.98
rp = 0.10
p = 0.61
Gender
    Male
    Female
1.91 ± 0.46
2.08 ± 0.33
t = 1.12, p = 0.27
1.66 ± 0.36
1.65 ± 0.32
t = 0.05, p = 0.96
Education (years) rp = −0.16
p = 0.43
rp = −0.002
p = 0.99
Total tremor score rp = −0.17
p = 0.36
rp = 0.11
p = 0.60
Tremor duration (years) rp = −0.19
p = 0.34
rp = 0.39
p = 0.06
MoCA score rp = −0.42
p = 0.03
rp = 0.16
p = 0.45
Median number of drinks of ethanol per month rs = 0.03
p = 0.86
rs = 0.16
p = 0.43
Values represent correlation coefficients (rp = Pearson’s and rs = Spearman’s) or mean ± standard deviation.
MoCA = Montreal Cognitive Assessment
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